- Home
- ZURA vs KRNY Comparison
ZURA vs KRNY Comparison
Compare ZURA & KRNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZURA | KRNY |
|---|---|---|
| Founded | 2022 | 1884 |
| Country | United States | United States |
| Employees | 40 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Savings Institutions |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.4M | 495.9M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | ZURA | KRNY |
|---|---|---|
| Price | $4.37 | $8.20 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $13.00 | $9.25 |
| AVG Volume (30 Days) | ★ 627.8K | 271.9K |
| Earning Date | 05-14-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 5.45% |
| EPS Growth | N/A | ★ 130.22 |
| EPS | N/A | ★ 0.46 |
| Revenue | N/A | ★ $2,580,000.00 |
| Revenue This Year | N/A | $3.89 |
| Revenue Next Year | N/A | $17.52 |
| P/E Ratio | ★ N/A | $17.87 |
| Revenue Growth | N/A | ★ 36.00 |
| 52 Week Low | $0.99 | $5.76 |
| 52 Week High | $7.25 | $8.50 |
Technical Indicators
Market Signals| Indicator | ZURA | KRNY |
|---|---|---|
| Relative Strength Index (RSI) | 38.08 | 57.51 |
| Support Level | $3.33 | $7.77 |
| Resistance Level | $4.58 | $8.27 |
| Average True Range (ATR) | 0.36 | 0.17 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 26.33 | 89.69 |
Price Performance
Historical ComparisonAbout ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
About KRNY Kearny Financial Corp
Kearny Financial Corp is a federally-chartered stock savings bank. The bank is engaged in the business of attracting deposits from the general public in New Jersey and New York, and using these deposits, together with other funds, to originate or purchase loans for its portfolios and invest in securities. The bank's loan portfolio is chiefly comprised of loans collateralized by commercial and residential real estate. The bank's primary source of income is net interest income.